Ret proto-oncogene. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Regorafenib CHEMBL1946170 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
ChEMBL only | 43 |
| Alectinib CHEMBL1738797 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
ChEMBL only | 24 |
| Sunitinib CHEMBL535 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Selpercatinib CHEMBL4559134 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor Inhibitor Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Sorafenib CHEMBL1336 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Pralsetinib CHEMBL4582651 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor Inhibitor Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
✓ Both | 9 |
| Quizartinib CHEMBL576982 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Sunitinib Malate CHEMBL1567 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Vandetanib CHEMBL24828 |
Tyrosine-protein kinase receptor RET inhibitor Inhibitor Small molecule |
✓ Both | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Breast cancer | 7 | Phase 3 |
| Acute myeloid leukemia | 4 | Phase 3 |
| Non-small cell lung carcinoma | 4 | Phase 3 |
| Colorectal cancer | 3 | Phase 3 |
| Hepatocellular carcinoma | 3 | Phase 3 |
| Glioblastoma | 3 | Phase 2/3 |
| Age-related macular degeneration | 3 | Phase 2 |
| Digestive system neoplasm | 3 | Phase 2 |
| Thyroid gland carcinoma | 3 | Phase 2 |
| Cancer | 2 | Phase 3 |
| Colon carcinoma | 2 | Phase 3 |
| Differentiated thyroid carcinoma | 2 | Phase 3 |
| Exocrine pancreatic carcinoma | 2 | Phase 3 |
| Gastrointestinal stromal tumor | 2 | Phase 3 |
| Kidney cancer | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
